TGTX TG Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

TGTX [NASD]

TG Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-2.01	Insider Own	1.20%	Shs Outstand	105.46M	Perf Week	7.67%
Market Cap	2.54B	Forward P/E	-	EPS next Y	-1.20	Insider Trans	-0.52%	Shs Float	84.68M	Perf Month	-8.18%
Income	-188.80M	PEG	-	EPS next Q	-0.34	Inst Own	61.20%	Short Float	18.60%	Perf Quarter	8.29%
Sales	0.20M	P/S	12723.70	EPS this Y	14.90%	Inst Trans	5.05%	Short Ratio	7.76	Perf Half Y	34.26%
Book/sh	-0.01	P/B	-	EPS next Y	23.60%	ROA	-162.50%	Target Price	-	Perf Year	211.86%
Cash/sh	0.64	P/C	32.46	EPS next 5Y	-	ROE	-	52W Range	4.95 - 24.76	Perf YTD	87.12%
Dividend	-	P/FCF	-	EPS past 5Y	-3.60%	ROI	-249.30%	52W High	-16.11%	Beta	2.42
Dividend %	-	Quick Ratio	1.40	Sales past 5Y	-0.10%	Gross Margin	-	52W Low	319.60%	ATR	1.25
Employees	153	Current Ratio	1.40	Sales Q/Q	0.00%	Oper. Margin	-	RSI (14)	50.19	Volatility	6.02% 5.98%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-17.70%	Profit Margin	-	Rel Volume	0.46	Prev Close	20.39
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	2.03M	Price	20.77
Recom	1.70	SMA20	-4.73%	SMA50	3.60%	SMA200	51.86%	Volume	1,029,460	Change	1.86%

Jun-05-20

Initiated

Evercore ISI

Outperform

$60

Jan-17-20

Reiterated

H.C. Wainwright

Buy

$20 → $24

Nov-27-19

Resumed

B. Riley FBR

Buy

$12

Feb-06-19

Resumed

Jefferies

Buy

Sep-25-18

Downgrade

Raymond James

Strong Buy → Outperform

Mar-09-18

Reiterated

B. Riley FBR, Inc.

Buy

$21.50 → $27

Dec-01-17

Resumed

B. Riley FBR, Inc.

Buy

$21.50

Nov-14-17

Resumed

H.C. Wainwright

Buy

$33

Apr-25-17

Initiated

Jefferies

Buy

Mar-06-17

Reiterated

FBR & Co.

Outperform

$24 → $26

Oct-06-16

Resumed

Brean Capital

Buy

$28

May-27-16

Initiated

SunTrust

Buy

$18

Dec-01-15

Initiated

FBR Capital

Outperform

$29

Sep-09-15

Initiated

Raymond James

Strong Buy

Aug-12-15

Resumed

H.C. Wainwright

Buy

$22

Jun-19-15

Reiterated

Brean Capital

Buy

$22 → $28

Dec-11-14

Reiterated

ROTH Capital

Buy

$25 → $33

Dec-10-14

Reiterated

ROTH Capital

Buy

$25 → $33

Oct-27-14

Initiated

H.C. Wainwright

Buy

$17

Sep-25-14

Reiterated

Brean Capital

Buy

$19 → $22

Jul-20-20 12:00PM	TG Therapeutics (TGTX) Moves to Buy: Rationale Behind the Upgrade Zacks
12:00PM	Are You Looking for a Top Momentum Pick? Why TG Therapeutics (TGTX) is a Great Choice Zacks
Jul-13-20 10:23AM	Did Hedge Funds Make The Right Call On TG Therapeutics Inc (TGTX) ? Insider Monkey -8.33%
Jul-08-20 07:00AM	TG Therapeutics Announces Publication in Blood Advances Describing Unique Immunomodulatory Effects on CLL T cells by Umbralisib GlobeNewswire +5.48%
Jun-22-20 09:00AM	TG Therapeutics Announces Preclinical Data Presentation at the 2020 American Association for Cancer Research Annual Meeting GlobeNewswire +6.55%
Jun-17-20 07:00AM	TG Therapeutics Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma GlobeNewswire
Jun-16-20 07:00AM	TG Therapeutics to Present at the Raymond James 2020 Human Health Innovation Conference GlobeNewswire
Jun-12-20 07:00AM	TG Therapeutics Announces Data Presentations at the 25th European Hematology Association (EHA) Annual Congress GlobeNewswire
Jun-09-20 05:29PM	Here's Why TG Therapeutics Jumped 58.6% in May Motley Fool
07:00AM	TG Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference GlobeNewswire
Jun-08-20 12:52PM	Hedge Funds Have Never Been This Bullish On TG Therapeutics Inc (TGTX) Insider Monkey
Jun-02-20 07:00AM	TG Therapeutics to Present at the Jefferies 2020 Healthcare Conference GlobeNewswire
May-29-20 08:15AM	TG Therapeutics Announces Final Results of the GENUINE Phase 3 Study Evaluating Ublituximab plus Ibrutinib in Previously Treated High-Risk Chronic Lymphocytic Leukemia at the 56th American Society of Clinical Oncology Annual Meeting GlobeNewswire -5.52%
May-15-20 07:00AM	TG Therapeutics Announces Preclinical Data Presentation at the Upcoming American Association for Cancer Research Annual Meeting GlobeNewswire
May-14-20 10:08PM	TG Therapeutics Announces Pricing of Upsized Public Offering of Common Stock GlobeNewswire
04:01PM	TG Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
09:27AM	TG Therapeutics Announces Data Presentations at Upcoming Medical Meetings GlobeNewswire
May-11-20 04:12PM	Were Hedge Funds Right About TG Therapeutics Inc (TGTX)? Insider Monkey +7.44%
04:00PM	TG Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results GlobeNewswire
May-08-20 07:00AM	TG Therapeutics Strengthens Executive Team with the Addition of Owen A. OConnor, MD, PhD, as Chief Scientific Officer GlobeNewswire
May-06-20 10:13AM	Should You Worry About TG Therapeutics, Inc.'s (NASDAQ:TGTX) CEO Pay? Simply Wall St. +14.92%
07:00AM	TG Therapeutics Raises Approximately $60 Million in Gross Proceeds Through its At-the-Market Facility GlobeNewswire
May-05-20 07:00AM	TG Therapeutics Announces Positive Topline Results from the UNITY-CLL Phase 3 Study Evaluating the Combination of Umbralisib and Ublituximab (U2) for the Treatment of Patients with Chronic Lymphocytic Leukemia GlobeNewswire +33.95%
May-01-20 12:30PM	Will TG Therapeutics (TGTX) Report Negative Q1 Earnings? What You Should Know Zacks
07:30AM	TG Therapeutics Announces Publication of Ublituximab Phase 2 Clinical Trial Results in Multiple Sclerosis Journal GlobeNewswire
Apr-29-20 07:20AM	TG Therapeutics Bolsters Board of Directors with the Appointment of Sagar Lonial, MD GlobeNewswire
Mar-25-20 12:00PM	TG Therapeutics (TGTX) Upgraded to Buy: What Does It Mean for the Stock? Zacks
06:19AM	Edited Transcript of TGTX earnings conference call or presentation 3-Mar-20 1:00pm GMT Thomson Reuters StreetEvents
Mar-22-20 10:39AM	Did You Manage To Avoid TG Therapeutics's (NASDAQ:TGTX) Painful 52% Share Price Drop? Simply Wall St.
Mar-09-20 08:00AM	TG Therapeutics Announces Data Presentations at the Upcoming American Academy of Neurology 72nd Annual Meeting GlobeNewswire -15.12%
Mar-05-20 11:00AM	TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the U.S. Food and Drug Administration for the Treatment of Follicular Lymphoma GlobeNewswire
Mar-03-20 07:00AM	TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2019 Financial Results GlobeNewswire
Feb-28-20 07:30AM	TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2019 Financial Results and Business Update GlobeNewswire
Jan-21-20 09:57AM	TG Therapeutics, Inc. (NASDAQ:TGTX) Insiders Increased Their Holdings Simply Wall St.
Jan-17-20 08:07AM	The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares Benzinga
Jan-16-20 07:30AM	TG Therapeutics Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma GlobeNewswire
Jan-10-20 08:56AM	Options Traders Expect Huge Moves in TG Therapeutics (TGTX) Stock Zacks
07:30AM	TG Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-24-19 09:54AM	TG Therapeutics (TGTX) Catches Eye: Stock Jumps 8.9% Zacks
07:24AM	The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict Benzinga
Dec-23-19 07:30AM	TG Therapeutics Announces $50.0 Million Registered Direct Public Offering of Common Stock to a Single Institutional Investor GlobeNewswire +8.90%
Dec-10-19 02:36PM	Hedge Funds Are Crazy About TG Therapeutics Inc (TGTX) Insider Monkey
09:26AM	TG Therapeutics' Shares Soar on Positive Early-Stage Data Zacks
Dec-09-19 08:58AM	TG Therapeutics shares rise on early-stage clinical data MarketWatch +30.34%
08:00AM	TG Therapeutics Announces Phase I Data Presentation for TG-1701, a Once-Daily BTK Inhibitor, as a Single Agent and in Triple Combination with Ublituximab and Umbralisib (U2), at the 61st American Society of Hematology Annual Meeting and Exposition GlobeNewswire
Dec-08-19 09:00AM	TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61st American Society of Hematology Annual Meeting and Exposition GlobeNewswire
Dec-07-19 08:35AM	The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling Benzinga
Dec-06-19 07:30AM	TG Therapeutics Recaps Schedule of Triple Therapy Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition GlobeNewswire -7.29%
Dec-03-19 09:29PM	Edited Transcript of TGTX earnings conference call or presentation 12-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-18-19 07:30AM	TG Therapeutics to Present at the Jefferies London Healthcare Conference GlobeNewswire
Nov-12-19 07:34AM	TG Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results GlobeNewswire
Nov-08-19 07:30AM	TG Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results and Business Update GlobeNewswire
Nov-06-19 09:15AM	TG Therapeutics Announces Triple Combination Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition GlobeNewswire
Nov-01-19 11:49AM	TG Therapeutics Inc (TGTX): Hedge Funds In Wait-and-See Mode Insider Monkey
Oct-30-19 05:15AM	2 Small Biotech Stocks Spurt Ahead on Positive Developments TheStreet.com
Oct-28-19 07:00AM	TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma GlobeNewswire +17.65%
Oct-24-19 07:30AM	TG Therapeutics Announces Final Long-Term Results from the Phase 3 GENUINE Study Demonstrated that Ublituximab in Combination with Ibrutinib Improved Progression-Free Survival in Patients with High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia as Compared to Ibrutinib Monotherapy GlobeNewswire
Oct-23-19 02:16PM	Is There An Opportunity With TG Therapeutics, Inc.'s (NASDAQ:TGTX) 30% Undervaluation? Simply Wall St.
Oct-02-19 07:30AM	TG Therapeutics to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire
Sep-30-19 07:30AM	TG Therapeutics Announces Publication of Clinical Data from the Phase I/Ib Combination Trial of Ublituximab and Umbralisib (U2) in Blood GlobeNewswire
Sep-23-19 07:30AM	TG Therapeutics Announces Data Presentations at the XVIII International Workshop on Chronic Lymphocytic Leukemia (iwCLL) GlobeNewswire
Sep-20-19 07:30AM	TG Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference GlobeNewswire -5.63%
Sep-17-19 01:33PM	Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way? Simply Wall St.
Sep-12-19 07:38AM	The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study Benzinga
07:30AM	TG Therapeutics Presents Data for Ublituximab at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) GlobeNewswire
Aug-29-19 07:30AM	TG Therapeutics Announces Data Presentations at the Upcoming 35th Annual Congress of ECTRIMS GlobeNewswire +5.44%
Aug-26-19 12:00PM	TG Therapeutics Mourns the Loss of Board Member, Mark Schoenebaum, MD GlobeNewswire
Aug-16-19 06:58AM	Edited Transcript of TGTX earnings conference call or presentation 9-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-12-19 04:52PM	Large Option Trader Sells TG Therapeutics Calls After Big Run Benzinga
06:08AM	What Kind Of Shareholder Owns Most TG Therapeutics, Inc. (NASDAQ:TGTX) Stock? Simply Wall St.
Aug-09-19 03:23PM	TG Therapeutics Inc (TGTX) Q2 2019 Earnings Call Transcript Motley Fool
07:30AM	TG Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results GlobeNewswire
Aug-07-19 04:05PM	TG Therapeutics to Host Conference Call on Second Quarter 2019 Financial Results and Business Update GlobeNewswire
Jul-31-19 01:48PM	Steven Cohen Charges Into Chiasma GuruFocus.com
Jul-09-19 10:43PM	Edited Transcript of TGTX earnings conference call or presentation 10-May-19 12:00pm GMT Thomson Reuters StreetEvents
Jul-05-19 05:14PM	Heres What Hedge Fund Think About TG Therapeutics Inc (TGTX) Insider Monkey
Jul-02-19 07:30AM	TG Therapeutics Announces Presentation of Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis During an Oral Session at the 5th Congress of the European Academy of Neurology GlobeNewswire
Jun-30-19 11:46PM	Weekly CEO Buys Highlight GuruFocus.com
Jun-27-19 12:27PM	Is TG Therapeutics, Inc.'s (NASDAQ:TGTX) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St. +14.33%
Jun-18-19 07:30AM	TG Therapeutics to Present at the Raymond James Life Sciences and MedTech Conference GlobeNewswire
Jun-17-19 07:30AM	TG Therapeutics Presents Preclinical Data for TG-1801, a First-in-Class Anti-CD47/CD19 Bispecific Antibody, at the 24th European Hematology Association Annual Congress GlobeNewswire
Jun-11-19 07:58AM	TG Therapeutics Confirms Registration Path for Umbralisib in Marginal Zone Lymphoma Following FDA Meeting GlobeNewswire
Jun-04-19 04:02PM	TG Therapeutics Presents Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 55th American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
07:30AM	TG Therapeutics to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire
May-28-19 09:28AM	TG Therapeutics May Have Potential but the Charts Need More Work TheStreet.com
May-23-19 07:20PM	TG Therapeutics CEO: Going through the process to reach big markets CNBC Videos
May-16-19 07:30AM	TG Therapeutics Announces Data Presentations at Upcoming Medical Meetings GlobeNewswire
May-10-19 01:23PM	TG Therapeutics Inc (TGTX) Q1 2019 Earnings Call Transcript Motley Fool -6.78%
07:31AM	TG Therapeutics: 1Q Earnings Snapshot Associated Press
07:00AM	TG Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results GlobeNewswire
May-09-19 07:30AM	TG Therapeutics to Host Conference Call on First Quarter 2019 Financial Results and Business Update GlobeNewswire
May-07-19 09:00AM	TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis at the American Academy of Neurology 71st Annual Meeting GlobeNewswire -5.68%
Apr-17-19 11:13AM	Can Core MedSurg Segment Drive Stryker's (SYK) Q1 Earnings? Zacks
Apr-16-19 09:28PM	Is TG Therapeutics a Buy? Motley Fool
03:17PM	Did TG Therapeutics, Inc. (NASDAQ:TGTX) Insiders Sell Shares? Simply Wall St.
Apr-15-19 07:30AM	TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the U.S. Food and Drug Administration for the Treatment of Marginal Zone Lymphoma GlobeNewswire
Apr-10-19 01:40PM	5 Oncology Companies That Are Set to Run GuruFocus.com +5.12%
Apr-08-19 10:00AM	3 Top Biotech Stocks to Buy in April Motley Fool
Apr-02-19 09:27AM	Company News For Apr 2, 2019 Zacks
Apr-01-19 01:46PM	TG Therapeutics Breaks Out on Positive Umbralisib Data Investopedia

TG Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and multiple sclerosis (MS). The company develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. It also develops Ublituximab, a novel anti-CD20 monoclonal antibody, which is in Phase III pivotal study for the treatment of CLL and MS; Umbralisib, a dual PI3K delta and CK1 epsilon inhibitor, which is in Phase III pivotal study for the treatment of CLL, and Phase 2b pivotal study for the treatment of marginal zone lymphoma and follicular lymphoma. In addition, the company develops TG-1501, an anti-PD-L1 monoclonal antibody, which is in Phase I pivotal study for the treatment of B-cell cancers; TG-1701, an oral Bruton's Tyrosine Kinase, which is in Phase I pivotal study for the treatment of B-cell cancers; and TG-1801, an anti-CD47/CD19 bispecific antibody that is in Phase I pivotal study for the treatment of B-cell cancers. TG Therapeutics, Inc. has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KENNEDY WILLIAM JAMES	Director	Jun 17	Sale	18.27	7,745	141,501	94,633	Jun 24 07:48 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience